Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, spanning multiple indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• B-cell Lymphoma
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Lymphoblastic Lymphoma
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndromes
• T-cell Lymphoma

Drugs mentioned

• Elzonris (tagraxofusp)

Snippet

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium | Conditions: Hematologic Malignancy, AML | Phase 1 | Status: RECRUITING